TY - JOUR
T1 - Brief Report
T2 - Long-Term (96-Week) Efficacy and Safety after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults
AU - Raffi, François
AU - Orkin, Chloe
AU - Clarke, Amanda
AU - Slama, Laurence
AU - Gallant, Joel
AU - Daar, Eric
AU - Henry, Keith
AU - Santana-Bagur, Jorge
AU - Stein, David K.
AU - Bellos, Nicholaos
AU - Scarsella, Anthony
AU - Yan, Mingjin
AU - Abram, Michael E.
AU - Cheng, Andrew
AU - Rhee, Martin S.
N1 - Publisher Copyright:
© 2017 The Author(s). Published by Wolters Kluwer Health, Inc.
PY - 2017/6/1
Y1 - 2017/6/1
N2 - In a double-blind, phase 3 trial, 663 HIV-infected, virologically suppressed adults were randomized to switch to tenofovir alafenamide (TAF; n = 333) vs. remain on tenofovir disoproxil fumarate (TDF; n = 330), each coformulated with emtricitabine (FTC), while continuing their third agent (boosted protease inhibitor or unboosted third agent). At week 96, 88.6% on FTC/TAF and 89.1% on FTC/TDF had HIV-1 RNA <50 copies per milliliter [adjusted difference -0.5% (95% confidence interval: -5.3 to 4.4%)]. Proteinuria, albuminuria, proximal renal tubular function, and bone mineral density improved after switching to TAF- from TDF-containing regimens. These longer-term data support FTC/TAF as a safe, well-tolerated, and durable nucleotide reverse transcriptase inhibitor backbone.
AB - In a double-blind, phase 3 trial, 663 HIV-infected, virologically suppressed adults were randomized to switch to tenofovir alafenamide (TAF; n = 333) vs. remain on tenofovir disoproxil fumarate (TDF; n = 330), each coformulated with emtricitabine (FTC), while continuing their third agent (boosted protease inhibitor or unboosted third agent). At week 96, 88.6% on FTC/TAF and 89.1% on FTC/TDF had HIV-1 RNA <50 copies per milliliter [adjusted difference -0.5% (95% confidence interval: -5.3 to 4.4%)]. Proteinuria, albuminuria, proximal renal tubular function, and bone mineral density improved after switching to TAF- from TDF-containing regimens. These longer-term data support FTC/TAF as a safe, well-tolerated, and durable nucleotide reverse transcriptase inhibitor backbone.
KW - HIV
KW - osteopenia
KW - proteinuria
KW - tenofovir alafenamide
UR - http://www.scopus.com/inward/record.url?scp=85014657477&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014657477&partnerID=8YFLogxK
U2 - 10.1097/QAI.0000000000001344
DO - 10.1097/QAI.0000000000001344
M3 - Article
C2 - 28272164
AN - SCOPUS:85014657477
SN - 1525-4135
VL - 75
SP - 226
EP - 231
JO - Journal of Acquired Immune Deficiency Syndromes
JF - Journal of Acquired Immune Deficiency Syndromes
IS - 2
ER -